3 results
Approved WMOCompleted
The primary objective is to compare PFS after treatment with tabalumab, bortezomib, anddexamethasone to that of placebo, bortezomib, and dexamethasone in patients with relapsed/refractory MM.Secondary objectives will include comparison of treatment…
Approved WMOPending
To evaluate the impact of electroencephalographic Narcotrend* Index (NI) monitoring on the speed of emergence and recovery from PPS for PGE.
Approved WMOCompleted
To evaluate the effect of crizanlizumab + standard of care compared to standard of care alone on albuminuria (ACR) decrease at 12 months